Tridek-One

Évry, France

Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.

$16.0M raised

Sep 2022

Venture - Series Unknown

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Tridek-One raised?

Tridek-One has raised $16.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2022.

Who are Tridek-One's investors?

Tridek-One's investors include Bpifrance, Pureos Bioventures, AdBio partners, Advent Life Sciences, Bioqube Ventures.

Where is Tridek-One headquartered?

Tridek-One is headquartered in Évry, France.

What does Tridek-One do?

Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway.

What stage is Tridek-One at?

Tridek-One is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 15, 2022.

MLA

"Tridek-One — Funding & Investors." VCBacked, September 15, 2022, https://www.vcbacked.co/company/tridek-one. Accessed July 3, 2026.

APA

VCBacked. (2022). Tridek-One — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/tridek-one

Wikipedia (cite web)

{{cite web |title=Tridek-One — Funding & Investors |url=https://www.vcbacked.co/company/tridek-one |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 15, 2022.